Bayern Kapital acquires a stake in TNI medical
Landshut/Würzburg — Bayern Kapital is taking a first-time stake in TNI medical AG (TNI medical) from Würzburg with its EFRE innovation fund as part of a new financing round. The company develops, manufactures and sells devices for ventilation therapy in patients with the so-called respiratory distress syndrome. This syndrome includes COPD, a chronic obstructive pulmonary disease that is the fourth leading cause of death globally, according to the World Health Organization (WHO). Another new investor is the investment company GMH-Ventures GmbH. The existing investors SHS Gesellschaft für Beteiligungsmanagement mbH (SHS), Kreditanstalt für Wiederaufbau(KfW) and Pathena Sicar are also participating in this round. TNI medical intends to use the funds for the further development and worldwide approval of the products as well as for the development of further markets, especially in non-European countries such as the USA and China.
TNI medical AG, headquartered in Würzburg, Germany, was founded about ten years ago as a spin-off of seleon GmbH, an engineering service provider in the medical technology sector. Immediately after the spin-off, the company started developing the TNI softFlow high-flow ventilator. Another mainstay from the very beginning was the trade in diagnostic and therapeutic products. Following successful clinical trials of the ventilators, SHS Gesellschaft für Beteiligungsmanagement mbH (SHS) and Kreditanstalt für Wiederaufbau (KfW) took a stake in the company in 2010. TNI medical used the funds to further develop the product family.
Patients receive a warm, moist airflow directly into the nose without condensation through a thin, heated and noise-optimized nasal cannula with the ventilators from the TNI softFlow family. The flow rate of the air as well as the humidity can be precisely adjusted and oxygen can be added if necessary. This leads to effective treatment of patients. In addition, the products are uncomplicated to use, the nasal cannula is easy to put on or take off. In contrast, with many conventional ventilators with closed nasal and face masks, patients complain of limited comfort. When treated with TNI ventilators, the patient can continue to do simple things during therapy, such as eating, drinking, talking, or taking medications. TNI medical’s novel therapy not only achieves very good clinical results, but also means better tolerability for patients compared to traditional mask therapy. TNI medical products are suitable for use in clinics as well as at home.
The Bayern Kapital Innovationsfonds EFRE (BKE) is funded by the European Union from the European Regional Development Fund (ERDF). BKE primarily finances innovative technology companies that are located outside the Munich metropolitan area and want to use BKE’s equity capital to develop new products and production processes and launch and penetrate them on the market.
Dr. Georg Ried (photo), Managing Director of Bayern Kapital, says: “TNI medical has developed an outstanding technology that can help many people around the world. In doing so, the team at TNI medical has consistently thought of the product from the patient’s point of view. In addition to the good economic development, this aspect convinced us to invest in TNI medical.”
Reinhilde Spatscheck, Chairwoman of the Supervisory Board of TNI medical AG and Managing Director and Partner at SHS Gesellschaft für Beteiligungsmanagement, says: “TNI medical AG has achieved significant milestones in the development, approval and clinical testing of the TNI softFlow family in recent years. After achieving CE and FDA approval and soon hopefully CFDA approval, the time has come to consistently develop the very large market potential worldwide with the funds from the new financing round — both in clinics and in the homecare sector.”
About TNI Medical AG
TNI Medical AG develops, manufactures and distributes devices for respiratory therapy in patients with respiratory distress syndrome, such as chronic obstructive pulmonary disease (COPD). For more than ten years, the Würzburg-based company has stood for exactly one goal: to consistently develop nasal high-flow therapy in order to offer respiratory insufficiency patients respiratory support with maximum efficiency and comfort. Based on intensive research and realized through precise development work in nasal insufflation therapy (TNI), the TNI softFlow system generation offers the highest therapy quality for all age groups in the clinic as well as in homecare.
About Bayern Kapital
Bayern Kapital GmbH, based in Landshut, was founded in 1995 as a wholly owned subsidiary of LfA Förderbank Bayern on the initiative of the Bavarian state government. As the venture capital company of the Free State of Bavaria, Bayern Kapital provides equity capital to the founders of innovative high-tech companies and young, innovative technology companies in Bavaria. Bayern Kapital currently manages eleven investment funds with an investment volume of around 325 million euros. To date, Bayern Kapital has invested around 285 million euros of venture capital in some 265 innovative technology-oriented companies from a wide range of sectors, including life sciences, software & IT, materials & new materials, nanotechnology and environmental technology. As a result, more than 5,000 jobs have been permanently created in Bavaria in sustainable companies. www.bayernkapital.de